DK3468965T3 - 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indol-forbindelser til behandling af cancer - Google Patents
1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indol-forbindelser til behandling af cancer Download PDFInfo
- Publication number
- DK3468965T3 DK3468965T3 DK17728990.7T DK17728990T DK3468965T3 DK 3468965 T3 DK3468965 T3 DK 3468965T3 DK 17728990 T DK17728990 T DK 17728990T DK 3468965 T3 DK3468965 T3 DK 3468965T3
- Authority
- DK
- Denmark
- Prior art keywords
- dihydro
- cancer treatment
- indol compounds
- tetrahydropyranyl
- carbonyl
- Prior art date
Links
- YQMFDGVJPUGMNU-UHFFFAOYSA-N 2,3-dihydroindol-1-yl(oxan-2-yl)methanone Chemical class O1C(CCCC1)C(=O)N1CCC2=CC=CC=C12 YQMFDGVJPUGMNU-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348457P | 2016-06-10 | 2016-06-10 | |
| PCT/US2017/035097 WO2017213919A1 (en) | 2016-06-10 | 2017-05-31 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3468965T3 true DK3468965T3 (da) | 2020-06-15 |
Family
ID=59031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17728990.7T DK3468965T3 (da) | 2016-06-10 | 2017-05-31 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indol-forbindelser til behandling af cancer |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US10759786B2 (da) |
| EP (1) | EP3468965B1 (da) |
| JP (1) | JP6632746B2 (da) |
| KR (1) | KR102241258B1 (da) |
| CN (1) | CN109641881B (da) |
| AR (1) | AR108586A1 (da) |
| AU (1) | AU2017277833B2 (da) |
| BR (1) | BR112018072872A2 (da) |
| CA (1) | CA3027035C (da) |
| CL (1) | CL2018003543A1 (da) |
| CO (1) | CO2018013251A2 (da) |
| CR (1) | CR20180579A (da) |
| CY (1) | CY1123660T1 (da) |
| DK (1) | DK3468965T3 (da) |
| DO (1) | DOP2018000278A (da) |
| EA (1) | EA037419B1 (da) |
| EC (1) | ECSP19001734A (da) |
| ES (1) | ES2797981T3 (da) |
| HR (1) | HRP20200769T1 (da) |
| HU (1) | HUE050155T2 (da) |
| IL (1) | IL263497B (da) |
| JO (1) | JOP20170131B1 (da) |
| LT (1) | LT3468965T (da) |
| MA (1) | MA45224B1 (da) |
| MD (1) | MD3468965T2 (da) |
| ME (1) | ME03744B (da) |
| MX (1) | MX382877B (da) |
| MY (1) | MY197462A (da) |
| NZ (1) | NZ748500A (da) |
| PE (1) | PE20190378A1 (da) |
| PH (1) | PH12018502572A1 (da) |
| PL (1) | PL3468965T3 (da) |
| PT (1) | PT3468965T (da) |
| RS (1) | RS60322B1 (da) |
| SG (1) | SG11201809625RA (da) |
| SI (1) | SI3468965T1 (da) |
| TW (1) | TWI671294B (da) |
| UA (1) | UA122526C2 (da) |
| WO (1) | WO2017213919A1 (da) |
| ZA (1) | ZA201807688B (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| SG11202001685TA (en) | 2017-08-28 | 2020-03-30 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| US12275729B2 (en) * | 2017-11-01 | 2025-04-15 | Merck Sharp & Dohme Llc | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| EP3727374A4 (en) * | 2017-12-21 | 2021-11-10 | Merck Patent GmbH | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND AN IDO1 INHIBITOR FOR THE TREATMENT OF CANCER |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2020036837A1 (en) | 2018-08-17 | 2020-02-20 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors |
| TW202024093A (zh) | 2018-09-21 | 2020-07-01 | 美商安塔製藥公司 | 作為抗病毒劑之官能化雜環 |
| WO2020096871A1 (en) * | 2018-11-06 | 2020-05-14 | Merck Sharp & Dohme Corp. | Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors |
| EP3883570A4 (en) | 2018-11-21 | 2022-07-13 | Enanta Pharmaceuticals, Inc. | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN114105961B (zh) * | 2021-12-10 | 2023-09-12 | 海南梵圣生物科技有限公司 | 一种ido1抑制剂(ly-3381916)制备方法 |
| CN114213310B (zh) * | 2021-12-31 | 2024-02-23 | 中国药科大学 | 吲哚啉化合物及其衍生物、制备方法、药物组合物和应用 |
| EP4784170A1 (en) * | 2023-09-25 | 2026-08-05 | Myris Therapeutics, Inc. | Methods for and compositions of non-peg bioconjugates with ultra-high drug-to-agent ratio |
| WO2025140363A1 (zh) * | 2023-12-27 | 2025-07-03 | 海思科医药集团股份有限公司 | 一种苯基哌啶衍生物的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004027171D1 (de) * | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
| DK1879573T3 (da) * | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| US8536221B2 (en) * | 2008-02-07 | 2013-09-17 | Abbvie Inc. | Amide derivatives as positive allosteric modulators and methods of use thereof |
| CA3012229C (en) * | 2008-07-08 | 2020-11-10 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| NO2694640T3 (da) * | 2011-04-15 | 2018-03-17 | ||
| BR112015022462A8 (pt) * | 2013-03-15 | 2019-11-26 | Bristol Myers Squibb Co | inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores |
| WO2015150097A1 (en) * | 2014-04-04 | 2015-10-08 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| AR102537A1 (es) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| CA3048202A1 (en) * | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by inhibition of nonsense mediated decay |
-
2017
- 2017-05-24 JO JOP/2017/0131A patent/JOP20170131B1/ar active
- 2017-05-24 AR ARP170101413A patent/AR108586A1/es not_active Application Discontinuation
- 2017-05-25 TW TW106117300A patent/TWI671294B/zh not_active IP Right Cessation
- 2017-05-31 PL PL17728990T patent/PL3468965T3/pl unknown
- 2017-05-31 DK DK17728990.7T patent/DK3468965T3/da active
- 2017-05-31 US US16/307,612 patent/US10759786B2/en active Active
- 2017-05-31 JP JP2018563823A patent/JP6632746B2/ja not_active Expired - Fee Related
- 2017-05-31 ME MEP-2020-98A patent/ME03744B/me unknown
- 2017-05-31 SI SI201730252T patent/SI3468965T1/sl unknown
- 2017-05-31 BR BR112018072872-1A patent/BR112018072872A2/pt not_active Application Discontinuation
- 2017-05-31 HR HRP20200769TT patent/HRP20200769T1/hr unknown
- 2017-05-31 PE PE2018003199A patent/PE20190378A1/es unknown
- 2017-05-31 HU HUE17728990A patent/HUE050155T2/hu unknown
- 2017-05-31 UA UAA201811735A patent/UA122526C2/uk unknown
- 2017-05-31 EA EA201892479A patent/EA037419B1/ru unknown
- 2017-05-31 NZ NZ748500A patent/NZ748500A/en not_active IP Right Cessation
- 2017-05-31 SG SG11201809625RA patent/SG11201809625RA/en unknown
- 2017-05-31 RS RS20200623A patent/RS60322B1/sr unknown
- 2017-05-31 MX MX2018015275A patent/MX382877B/es unknown
- 2017-05-31 PT PT177289907T patent/PT3468965T/pt unknown
- 2017-05-31 US US15/609,115 patent/US9872853B2/en not_active Expired - Fee Related
- 2017-05-31 CR CR20180579A patent/CR20180579A/es unknown
- 2017-05-31 EP EP17728990.7A patent/EP3468965B1/en active Active
- 2017-05-31 LT LTEP17728990.7T patent/LT3468965T/lt unknown
- 2017-05-31 MD MDE20190462T patent/MD3468965T2/ro not_active IP Right Cessation
- 2017-05-31 KR KR1020187035215A patent/KR102241258B1/ko not_active Expired - Fee Related
- 2017-05-31 WO PCT/US2017/035097 patent/WO2017213919A1/en not_active Ceased
- 2017-05-31 AU AU2017277833A patent/AU2017277833B2/en not_active Ceased
- 2017-05-31 CA CA3027035A patent/CA3027035C/en active Active
- 2017-05-31 CN CN201780035976.4A patent/CN109641881B/zh not_active Expired - Fee Related
- 2017-05-31 MA MA45224A patent/MA45224B1/fr unknown
- 2017-05-31 ES ES17728990T patent/ES2797981T3/es active Active
- 2017-05-31 MY MYPI2018002369A patent/MY197462A/en unknown
-
2018
- 2018-11-15 ZA ZA2018/07688A patent/ZA201807688B/en unknown
- 2018-12-04 IL IL263497A patent/IL263497B/en active IP Right Grant
- 2018-12-06 CO CONC2018/0013251A patent/CO2018013251A2/es unknown
- 2018-12-06 PH PH12018502572A patent/PH12018502572A1/en unknown
- 2018-12-10 DO DO2018000278A patent/DOP2018000278A/es unknown
- 2018-12-10 CL CL2018003543A patent/CL2018003543A1/es unknown
-
2019
- 2019-01-09 EC ECSENADI20191734A patent/ECSP19001734A/es unknown
-
2020
- 2020-06-05 CY CY20201100508T patent/CY1123660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3580211T3 (da) | 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer | |
| LT3468965T (lt) | 1-tetrahidropiranilkarbonil-2,3-dihidro-1h-indolo junginiai vėžio gydymui | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3431105T3 (da) | Medicinsk sammensætning til behandling af cancer | |
| DK3582853T3 (da) | Cykliske dinukleotidforbindelser til behandling af cancer | |
| DK3478286T3 (da) | Fremgangsmåder til behandling af ovariecancer | |
| DK3559265T3 (da) | Fremgangsmåde til behandling af polynukleotider | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| SI3365373T1 (sl) | Vezne molekule, ki zaviranjo rast raka | |
| DK3389778T3 (da) | Indretning til fotodynamisk behandling | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| DK3374359T3 (da) | Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer | |
| LT3377488T (lt) | Heterocikliniai junginiai, kaip imunomoduliatoriai | |
| DK3377516T3 (da) | Sammensætning til behandling af cancer | |
| DK3509893T3 (da) | Fremgangsmåde til roaming | |
| HUE054784T2 (hu) | 5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| PL3197456T3 (pl) | Leczenie nowotworów | |
| IL260082B (en) | Small molecules against cancer | |
| DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
| DK3303616T3 (da) | Fremgangsmåder til prognose af prostatakræft | |
| DK3353177T3 (da) | Tricykliske heterocykler til behandling af cancer | |
| DK3394089T3 (da) | Polypeptider til inhibering af komplementaktivering | |
| IL265751B (en) | Immunogenic compounds for cancer therapy | |
| DK3393468T3 (da) | Fremgangsmåder til behandling af en immundefektsygdom |